Cagrilintide
AM833 / Cagri: CagriSema Trial Evidence, Approval Status & Verified Vendor Prices
Cagrilintide (AM833) — Long-Acting Amylin Analogue
Last reviewed: 14 October 2026
Cagrilintide is Novo Nordisk's long-acting version of amylin, the hormone released alongside insulin that tells you you are full. On its own it produced about 11% weight loss in a phase 2 trial; paired with semaglutide as CagriSema it produced about 20% in phase 3, and that combination is under FDA review.
It activates amylin and calcitonin receptors in the brain to reduce appetite, and slows how fast food leaves the stomach. Because that is a different pathway from GLP-1, adding it to semaglutide gave more weight loss than semaglutide alone in the REDEFINE 1 trial.
It is the first amylin analogue to reach a phase 3 obesity programme, and the pairing with semaglutide is Novo's answer to tirzepatide and retatrutide. The research market picked it up in 2026 and it is now sold by most GLP-class vendors, often alongside blends.
Not approved anywhere; the combination is under review with a decision expected late 2026. Research-grade cagrilintide has no evidence of its own. Verify identity and the lot certificate at the laboratory, and do not compare a blend vial with a single-compound vial.
What is Cagrilintide?
Cagrilintide (AM833) is a long-acting amylin analogue developed by Novo Nordisk. Amylin is the hormone co-secreted with insulin by pancreatic beta cells that slows gastric emptying and signals satiety through the area postrema and hypothalamus. Cagrilintide keeps that activity, adds activity at calcitonin receptors, and is engineered for once-weekly subcutaneous exposure through a fatty diacid side chain that binds albumin.
It is not approved anywhere on its own and has no regulatory filing as a single agent. Its route to market is the fixed-dose combination with semaglutide, CagriSema: Novo Nordisk filed the New Drug Application with the FDA on 18 December 2025 on the REDEFINE 1 and REDEFINE 2 results, a decision is expected in the last quarter of 2026, and in February 2026 the REDEFINE 4 head-to-head missed non-inferiority against tirzepatide. Status verified 14 October 2026.
On the research market cagrilintide is newer than the GLP-class compounds. Most vendors list it by name or as "Cagri"; blends with semaglutide (CagriSema-style) and with retatrutide are sold at a range of ratios and are not interchangeable with single-compound vials. The vendor table on this page compares single-compound vials only.
- Cagrilintide (AM833) is a once-weekly amylin analogue that also activates calcitonin receptors; its satiety pathway is separate from GLP-1.
- Phase 2 monotherapy: −10.8% body weight at 26 weeks on 4.5 mg (Lau et al., Lancet 2021). REDEFINE 1 with semaglutide: −20.4% at 68 weeks vs −2.3% placebo (NEJM 2025).
- Not approved anywhere. CagriSema NDA filed with the FDA 18 Dec 2025; decision expected Q4 2026. REDEFINE 4 missed non-inferiority against tirzepatide (Feb 2026).
- Most research vendors list it by name or as 'Cagri'; blends with semaglutide or retatrutide are sold at various ratios and are not comparable with single vials.
- Research-grade cagrilintide is not the trial product and the trial evidence does not transfer to it. Verify the lot certificate at the laboratory before relying on it.
Molecular Composition
Cagrilintide is a 37-residue acylated peptide built on the human amylin backbone. Three proline substitutions (the same strategy used in pramlintide) prevent the fibrillation that makes native amylin unusable as a drug, calcitonin-derived residues in the mid-region broaden receptor engagement, and a C20 fatty diacid attached through a linker binds albumin to extend the half-life to roughly one week. The developer has not published the full sequence; vendor certificates identify it by mass and retention time against a reference standard.
How Does It Work?
Cagrilintide copies the satiety hormone amylin and lasts a week per dose: it acts on amylin and calcitonin receptors in the brainstem and hypothalamus, a satiety pathway separate from GLP-1, which is why it is being combined with semaglutide.
Cagrilintide is a dual amylin and calcitonin receptor agonist. Amylin receptors are complexes of the calcitonin receptor with receptor activity-modifying proteins (RAMP1–3); cagrilintide activates both the amylin receptor complexes and the calcitonin receptor itself, which is why it is described as a DACRA (dual amylin and calcitonin receptor agonist).
The weight effect is mainly central: amylin-receptor signalling in the area postrema and hypothalamus reduces food intake and increases satiety through a pathway distinct from GLP-1. That is the rationale for pairing it with semaglutide: the two act on separate satiety circuits, and in the REDEFINE 1 trial the combination produced more weight loss than semaglutide 2.4 mg alone at the same 68-week timepoint. Peripherally, amylin agonism slows gastric emptying and suppresses post-meal glucagon.
Key Research Pathways
Amylin Receptor Signalling
Activates calcitonin-receptor/RAMP complexes in the area postrema and hypothalamus, reducing food intake and increasing satiety.
Calcitonin Receptor Agonism
Direct calcitonin-receptor activity in addition to amylin-receptor activity; the basis of the DACRA classification.
Gastric Emptying
Slows gastric emptying and suppresses post-prandial glucagon, as native amylin does.
Albumin Binding (Fatty Diacid)
C20 fatty diacid side chain binds albumin, extending the half-life to about a week.
Key Findings from the Literature
- Phase 2 monotherapy (Lau et al., Lancet 2021, n=706): −10.8% body weight at 26 weeks on 4.5 mg weekly vs −3.0% placebo and −9.0% liraglutide 3.0 mg
- Phase 1b with semaglutide (Enebo et al., Lancet 2021): co-administration was tolerated and produced greater weight loss than semaglutide alone over 20 weeks
- Phase 2 in type 2 diabetes (Frias et al., Lancet 2023, n=92): CagriSema 2.4/2.4 mg lowered HbA1c and body weight more than either component alone at 32 weeks
- REDEFINE 1 (NEJM 2025, n=3,417): CagriSema −20.4% body weight at 68 weeks (treatment-policy estimand) vs −2.3% placebo; −22.7% in the trial-product estimand
- Acts through amylin and calcitonin receptors, a satiety pathway separate from GLP-1R
- Not approved anywhere; CagriSema NDA filed with the FDA 18 Dec 2025, decision expected Q4 2026 (verified 14 Oct 2026)
Important Research Context
Research References
Peer-reviewed literature supporting the research profile of Cagrilintide
The following peer-reviewed studies form the primary evidence base for Cagrilintide's research profile. All references are sourced from PubMed, NCBI, and peer-reviewed scientific journals. Published research is available through PubMed, NCBI, and peer-reviewed biomedical journals.
- 1.
Lau DCW, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. The Lancet. 2021.PMID: 34798060
−10.8% body weight at 26 weeks on cagrilintide 4.5 mg vs −3.0% placebo and −9.0% liraglutide 3.0 mg (n=706).
- 2.
Enebo LB, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management. The Lancet. 2021.PMID: 33894837
Phase 1b: co-administration with semaglutide 2.4 mg was tolerated and produced greater weight loss than semaglutide alone over 20 weeks.
- 3.
Frias JP, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. The Lancet. 2023.PMID: 37364590
CagriSema lowered HbA1c and body weight more than semaglutide or cagrilintide alone at 32 weeks (n=92).
- 4.
Garvey WT, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1). New England Journal of Medicine. 2025.PMID: 40544433
−20.4% body weight at 68 weeks on CagriSema vs −2.3% placebo (treatment-policy estimand; −22.7% trial-product estimand), n=3,417.
Cagrilintide
Metabolic Research
Purgo Labs list price, read 12 Sep 2026 · per-lot COA on the vendor page
Purgo Labs does not list Cagrilintide (checked 26 Sep 2026)
Fast FedEx shipping · Discreet packaging
Technical Specifications
| Peptide Class | Long-acting amylin analogue (DACRA), 37 AA, lipidated |
| Receptor Targets | Amylin receptors (CTR + RAMP1–3) and calcitonin receptor |
| Half-life | ~1 week (once-weekly dosing in trials) |
| Developer / Code | Novo Nordisk, AM833 |
| Clinical Stage | CagriSema NDA under FDA review (filed 18 Dec 2025); no filing for cagrilintide alone |
| Common Vial Sizes | 5mg and 10mg (vendor-dependent) |
| Form | Lyophilized powder |
| Purity | ≥99% (third-party tested) |
View full legal status guide →
Where to buy Cagrilintide
Purgo Labs does not list this compound — every scored vendor that does, with dated prices
Other Compounds in This Guide
Supporting Research
Cagrilintide has human randomised evidence as monotherapy (phase 2) and as part of CagriSema (phase 2 and phase 3). Efficacy claims can be stated with confidence when tied to those trials of the pharmaceutical product; nothing has been shown for research-grade vials.
References
- Lau DCW, et al.[HUMAN Phase 2 RCT, n=706]−10.8% body weight at 26 weeks on 4.5 mg weekly; dose-dependent effect across 0.3–4.5 mg.
- Garvey WT, et al.[HUMAN Phase 3 RCT, n=3,417]CagriSema −20.4% at 68 weeks vs −2.3% placebo; greater than semaglutide 2.4 mg or cagrilintide 2.4 mg alone.
- Frias JP, et al.[HUMAN Phase 2 RCT, n=92, type 2 diabetes]Greater HbA1c and weight reduction with the combination than with either component at 32 weeks.
Research Databases
Ready to Source Cagrilintide?
Purgo Labs does not currently list Cagrilintide. The ranking below covers every scored vendor that does, with dated product-page prices.